KEY POINTS
- This multicenter, open-label randomized trial evaluated megestrol acetate for preventing weight loss during curative-intent head and neck radiotherapy. Between April 2024 and July 2025, 102 patients with non-nasopharyngeal head and neck squamous cell carcinoma were randomized at three Thai institutions, with 51 patients per arm. Mean baseline weight was 51.6 kg, mean BMI 19.8 kg/m², and 72.3% received concurrent chemoradiotherapy. All patients were treated with IMRT using VMAT or helical tomotherapy.
- Megestrol acetate was administered at 800 mg orally once daily from the first day of radiotherapy until six weeks after treatment completion. The control arm received standard supportive care without megestrol. Both groups had access to nutritional assessment, dietary counseling, oral supplements, symptom management, and feeding tubes when clinically indicated. Gross disease or postoperative targets generally received 60–70 Gy, with elective nodal irradiation to 54–59.4 Gy.
- The primary endpoint significantly favored megestrol acetate. At six weeks after radiotherapy, mean body-weight change was +2.07 ± 4.90 kg with megestrol versus −1.74 ± 5.49 kg with standard care (p<0.01), corresponding to a 3.81-kg difference in mean weight change. At treatment week four, weight change was +0.16 versus −2.03 kg (p<0.001), and by week six it was −0.96 versus −2.53 kg (p=0.05). The per-protocol analysis also favored megestrol, supporting the primary finding.
- Weight preservation was driven primarily by changes in fat rather than skeletal muscle. At six weeks after RT, body fat percentage increased by 3.11 percentage points in the megestrol group but decreased by 1.90 points in controls (p<0.001). In contrast, mean muscle-mass change was −0.40 versus −0.18 kg (p=0.80), demonstrating no significant muscle-preservation benefit. Total body water percentage decreased more with megestrol (−4.54 versus +0.52 percentage points; p<0.001). Body composition was estimated using bioelectrical impedance rather than CT or DEXA.
- The effect appeared more pronounced in patients without feeding tubes at baseline, but this was exploratory. Among patients without feeding tubes, mean weight change at six weeks after RT was +1.92 kg with megestrol versus −3.00 kg with standard care (p<0.001). Among those with feeding tubes, corresponding changes were +2.69 versus +1.95 kg (p=0.70). Because these subgroup comparisons were post hoc and involved relatively small numbers, they cannot establish a differential treatment effect based on feeding-tube status.
- Improved body weight did not translate into sustained quality-of-life or appetite benefits. FACT-G total scores improved by 5.9% from baseline at week four in the megestrol group versus a 3.5% decrease in controls (p=0.04), but no significant differences persisted at treatment completion or six weeks afterward. Appetite-related FAACT Anorexia/Cachexia scores were not significantly different between groups at the assessed time points. Radiotherapy completion was also comparable, with four patients in each group failing to complete the prescribed course.
- Short-term adverse events were limited, but safety conclusions remain uncertain. Three patients receiving megestrol developed rash, including one grade 1 and two grade 2 events; one discontinued the medication because of rash. No thromboembolic events, grade 4 toxicity, or treatment-related serious adverse events were reported. However, patients with thromboembolic disease, significant cardiovascular conditions, poorly controlled hypertension or diabetes, and conditions predisposing to edema were excluded. Follow-up ended six weeks after RT, limiting assessment of rare adverse events, long-term body composition, and survival.
CLINICAL TAKEAWAY
Megestrol acetate significantly improved short-term weight preservation during modern head and neck radiotherapy when added to standard nutritional and supportive care. However, the additional weight was predominantly fat rather than muscle, without a sustained improvement in appetite or quality of life. These findings support selective consideration of megestrol but do not justify routine prophylactic administration without weighing thromboembolic and other potential risks.